TRANSFORMING THE LIVES OF INDIVIDUALS
AND FAMILIES FIGHTING HEART DISEASE
Tenaya Therapeutics is a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease.
Tenaya is founded by world-leading scientists from the Gladstone Institute’s Cardiovascular Division and the University of Texas Southwestern Medical Center.
Tenaya seeks to address heart disease through three distinct and multi-modality platforms: a Regeneration Platform, a Gene Therapy Platform, and a Precision Medicine Platform.
LATEST NEWS
The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases
Our CEO, Faraz Ali, authored an article for Cell & Gene Therapy Insights discussing the opportunities and challenges of developing cell and gene therapies for cardiovascular disease. Cardiovascular diseases, especially orphan indications, are vastly underrepresented in research on regenerative medicine and advanced therapy, but recent advancements suggest an evolving landscape for treating heart disease with cell and gene therapies.
Read MoreTenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver potentially curative therapies that target the underlying causes of heart disease, today announced that it will present preclinical data from four studies as posters at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), being held May 12-15, 2020, in a virtual format.
Read MoreTenaya Therapeutics Closes $92 Million Series B Financing
– Proceeds advance heart disease projects from three product platforms toward the clinic –
SOUTH SAN FRANCISCO, Calif., October 3, 2019 – Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease, today announced the successful completion of a $92 million Series B financing.
Read MoreJoin Our Team
Are you ambitious, driven, energized by scientific innovation and committed to making a difference for patients suffering from heart disease? Do you value a culture grounded in science and teamwork? We are looking for experienced biopharmaceutical professionals and scientists to join the Tenaya team who want to help us advance our mission of using cutting-edge science and precision medicine to develop innovative therapies to transform the treatment of heart disease.